UNITED STATES—A new report from Yale School of Medicine professor Harvey Risch, released May 27 reveals evidence of efficacy of hydroxychloroquine+azithromycin as a COVID-19 treatment for symptomatic high-risk patients.
Hydroxychloroquine is a drug used to treat and prevent malaria, it can also treat lupus and rheumatoid arthritis. It is currently still under study as a possible treatment for COVID-19. It has yet to be approved by the FDA for COVID-19 treatment.
The report stated, “Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy.”
The report calls for the widespread promotion and availability of hydroxychloroquine and azithromycin to physicians.
President Trump promoted the use of hydroxychloroquine, and started taking the anti-malaria drug as a prophylactic against COVID-19.
POTUS stated on May 18, that “A lot of good things have come out. You’d be surprised at how many people are taking it, especially the front-line workers. Before you catch it. The front-line workers, many, many are taking it.”
There is no published data that proves that the medication protects against infection with the coronavirus, experts recommend such use only within clinical trials.
A study released May 22, found that 96,000 coronavirus patients across six different continents that were treated with hydroxychloroquine died at higher rates than those who did not receive the treatment.
